The U.S. continues to charge significantly higher prices for prescription drugs compared with similarly wealthy countries.

Sangamo Therapeutics said on Monday that partner Pfizer has terminated their hemophilia A gene therapy co-development ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. *Stock prices ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

PF-07826390 is under development for the treatment of solid tumors including non-small cell lung cancer, colorectal cancer and renal cell carcinoma. It acts by targeting leukocyte immunoglobulin like ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the ...

While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...

The pharma giant pulled out of its partnership with Sangamo, signalling unsteady waters for the latter company and the future ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...